Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

932
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
932
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

405
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
405
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mean Arterial Pressure During the First 24 Hours After Cardiac Surgery and Acute Kidney Injury: An Observational Cohort Study.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Comparison of machine learning methods for prediction of venous thromboembolism among hospitalized adults.

Journal of hospital medicine·2026
Same author

Development and external validation of the NEO-READY model to predict date of discharge among premature neonatal intensive care patients.

medRxiv : the preprint server for health sciences·2026
Same author

Sex-biased immune rewiring may underlie reduced risk for cardiac allograft vasculopathy in females following heart transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Summary of radiation effects on incidence of solid cancers in the Life Span Study of atomic bomb survivors: 1958-2009.

Carcinogenesis·2025
Same author

Adolescent Mental Health Theme Issue-Adolescent Suicide, Eating Disorders, and the Role of Systems in Mental Health.

JAMA pediatrics·2025
Same journal

Correction to I.M. Matters News: Sleep medicine for seniors.

Annals of internal medicine·2026
Same journal

Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

Annals of internal medicine·2026
Same journal

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026
Same journal

Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

Annals of internal medicine·2026
Same journal

Grappling with GLP-1 prescribing.

Annals of internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Statins and cognitive function: a systematic review.

Karl Richardson, Marisa Schoen, Benjamin French

    Annals of Internal Medicine
    |November 20, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Current evidence does not suggest statins negatively impact cognition. However, more robust studies are needed to confirm these findings, especially concerning high-dose statin use.

    More Related Videos

    Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
    07:30

    Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

    Published on: April 23, 2021

    2.6K
    Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
    04:33

    Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

    Published on: April 26, 2024

    1.8K

    Related Experiment Videos

    Last Updated: May 5, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    14.8K
    Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
    07:30

    Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

    Published on: April 23, 2021

    2.6K
    Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
    04:33

    Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

    Published on: April 26, 2024

    1.8K

    Area of Science:

    • Cardiovascular Pharmacology
    • Neuroscience
    • Evidence Synthesis

    Background:

    • The U.S. Food and Drug Administration (FDA) issued a warning regarding potential cognitive impairment associated with statin use.
    • The precise relationship between statin medications and cognitive function remains incompletely understood.

    Purpose of the Study:

    • To systematically examine the existing evidence on the effects of statins on cognitive function.
    • To evaluate the association between statin therapy and cognitive outcomes, including dementia and mild cognitive impairment.

    Main Methods:

    • Conducted a comprehensive literature search of PubMed, Embase, and Cochrane Library up to October 2012.
    • Included randomized controlled trials (RCTs) and observational studies (cohort, case-control, cross-sectional) assessing cognition in statin users.
    • Utilized FDA postmarketing surveillance data from January 1986 through March 2012.

    Main Results:

    • Low-quality evidence indicated no increased incidence of Alzheimer disease or differences in procedural memory, attention, or motor speed among statin users.
    • Moderate-quality evidence showed no increased incidence of dementia or mild cognitive impairment, nor changes in global cognitive performance, executive function, or processing speed.
    • FDA data revealed low and comparable reporting rates for cognitive adverse events with statins versus other cardiovascular drugs.

    Conclusions:

    • The overall strength of evidence for statins' effects on cognition is limited (low to moderate) due to a lack of well-powered RCTs.
    • Imprecision, inconsistency, and risk of bias in existing studies restrict definitive conclusions.
    • While published data do not indicate an adverse effect of statins on cognition, larger, well-designed studies are necessary for unequivocal findings, particularly for high-dose statins.